Dr. Andrew Currin is Co-Founder and Chief Scientific Officer at Imperagen, a pioneering TechBio company spun out of the University of Manchester that uses AI and quantum physics to engineer better enzymes faster.

Andrew is a leading expert in directed evolution, enzymology, and synthetic biology, having conducted research at the Manchester Institute of Biotechnology before co-founding Imperagen in 2021.

As the architect of Imperagen's patented gene assembly technologies, Andrew drives the automated enzyme engineering platform underpinning the company's Digital Enzyme Evolution approach.

Prior to Imperagen, Andrew was involved in the founding and IPO of C4X Discovery in 2014, demonstrating a track record of building and scaling deep science ventures.

Imperagen's AI-guided closed-loop system has achieved enzyme productivity improvements of up to 677x in just five development cycles, with clients spanning Fortune 500 personal care and pharmaceutical manufacturing companies.